Bonavina Luigi, Arini Andrea, Ficano Leonardo, Iannuzziello Donato, Pasquale Luigi, Aragona Salvo Emanuele, Ciprandi Giorgio, On Digestive Disorders Italian Study Group
Surgery Unit, San Donato Hospital, Milan, Italy.
Acta Biomed. 2019 Jul 10;90(7-S):18-23. doi: 10.23750/abm.v90i7-S.8651.
Abdominal surgery represents a high risk for hospital-acquired infections and complication that may compromise the surgery outcome. Patients with recent abdominal surgery have an intestinal dysbiosis. There is evidence that probiotics may counterbalance the impaired microbiota. Therefore, the current survey evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 612 outpatients (344 males and 268 females, mean age 58 years) undergoing digestive surgery. Patients took 1 stick/daily for 8 weeks. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing digestivesurgery.
腹部手术是医院获得性感染和并发症的高风险因素，这些感染和并发症可能会影响手术结果。近期接受腹部手术的患者存在肠道菌群失调。有证据表明益生菌可能会平衡受损的微生物群。因此，本调查评估了阿宾可（Abincol®）的疗效和安全性，这是一种口服营养补充剂，含有植物乳杆菌LP01（10亿个活细胞）、乳酸乳球菌亚种cremoris LLC02（8亿个活细胞）和德氏乳杆菌LDD01（2亿个活细胞）的益生菌混合物，研究对象为612名接受消化手术的门诊患者（344名男性和268名女性，平均年龄58岁）。患者每天服用1支，持续8周。阿宾可（Abincol®）显著减轻了肠道症状的出现和严重程度，并改善了粪便形态。总之，本调查表明，在接受消化手术患者的管理中，阿宾可（Abincol®）可被视为一种有效且安全的治疗选择。
